A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (NCT05675449)
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when given in combination with carfilzomib plus dexamethasone. Part 2 has 2 arms. The first will evaluate the safety and tolerability of elranatamab when given in combination with maplirpacept. The second will identify the optimal dose(s) of elranatamab plus maplirpacept. All study medicines are given over 4-week cycles. Everyone taking part in this study will receive elranatamab as a shot under the skin. Participants in Part 1 will also receive weekly carfilzomib as an IV infusion (given directly into a vein) and dexamethasone either by mouth (as a pill) or by IV infusion. Participants in Part 2 will receive elranatamab in combination with maplirpacept as an IV infusion (given directly into a vein) The investigators will examine the experiences of people receiving the study medicines. This will help determine if the study medicines are safe and can be used for multiple myeloma treatment. Participants will take part in this study for about 2 years after the first dose.
Who can join: Review the eligibility criteria below.
Location: University of Arkansas for Medical Sciences — Little Rock, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (36 Sites)
Showing the first 25 of 36 sites.
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Beverly Hills Cancer Center — Beverly Hills, California
- Clinical Research Advisors (Encino Satellite Location) — Encino, California
- Clinical Research Advisors (Korea Town Satellite Location) — Los Angeles, California
- Clinical Research Advisors (West Hollywood Satellite Location) — Los Angeles, California
- Sylvester Comprehensive Cancer Center - Aventura — Aventura, Florida
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center — Coral Gables, Florida
- Sylvester Comprehensive Cancer Center - Coral Springs — Coral Springs, Florida
- University of Miami Hospital and Clinics - Deerfield Beach — Deerfield Beach, Florida
- Sylvester Comprehensive Cancer Center - Hollywood — Hollywood, Florida
- Griffin Cancer Research Building (GCRB) — Miami, Florida
- Sylvester Comprehensive Cancer Center — Miami, Florida
- University of Miami Hospital and Clinics — Miami, Florida
- Sylvester Comprehensive Cancer Center - Kendall — Miami, Florida
- Sylvester Comprehensive Cancer Center - Plantation — Plantation, Florida
- Emory University Hospital Midtown — Atlanta, Georgia
- Emory University Administration Office — Atlanta, Georgia
- Emory University Hospital — Atlanta, Georgia
- Winship Cancer Institute — Atlanta, Georgia
- State University of Iowa, Division of Sponsored Programs — Iowa City, Iowa
- University of Iowa Hospitals and Clinics — Iowa City, Iowa
- Oncology Investigational Drug Service,Department of Pharmacy Services — Baltimore, Maryland
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
- Johns Hopkins University Cancer Immunology/GI Oncology — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.